Lotus Neuro Launches to Advance Focused Ultrasound Drug Delivery for Neurological Diseases
Lotus Neuro, a clinical-stage biotechnology company focused on combining focused ultrasound with therapeutic medicines to address focal neurological diseases, has announced its public launch. The company is developing a technology platform designed to overcome one of the most persistent challenges in neuroscience drug development: delivering medicines across the blood-brain barrier (BBB) to precisely targeted regions of the brain.
Lotus Neuro was spun out of Insightec in December 2025 and is building its therapeutic development strategy around clinically validated focused ultrasound technology. While the parent organization continues to advance and commercialize focused ultrasound as a medical technology, Lotus Neuro is concentrating on its application as a drug-delivery modality for brain diseases.
The company believes that limitations in drug delivery have contributed to the failure of numerous neuroscience programs. Many potentially effective medicines cannot reach the brain in sufficient concentrations because the BBB tightly regulates the movement of substances from the bloodstream into brain tissue. As a result, a clinical trial that produces a negative outcome may reflect inadequate drug exposure rather than an ineffective therapeutic target.
Lotus Neuro is seeking to address this challenge by using focused ultrasound together with circulating microbubbles to temporarily and precisely modulate the BBB. The approach is intended to open the barrier in specific brain regions while a therapeutic is administered, potentially allowing medicines to reach areas that would otherwise remain difficult to access.
Targeted Blood-Brain Barrier Modulation
The BBB is essential for protecting the brain from potentially harmful substances circulating in the bloodstream. At the same time, this protective mechanism presents a major obstacle for pharmaceutical development because many drugs cannot cross the barrier efficiently.
Lotus Neuro’s platform uses focused ultrasound and circulating microbubbles to create targeted, temporary modulation of the BBB. The company says the technology can be applied to precisely defined brain volumes ranging from regions only a few millimeters across to substantially larger areas, including large hemispheric regions.
An important feature of the approach is that the therapeutic drug itself does not need to be chemically modified. This potentially allows the platform to be paired with a broad variety of therapeutic modalities.
The company says its approach can be combined with small-molecule drugs, antibodies, antibody-drug conjugates, enzymes, gene therapies, oligonucleotides and cell therapies. By remaining largely agnostic to the type of therapeutic being delivered, Lotus Neuro aims to work with pharmaceutical and biotechnology companies developing medicines across different areas of neuroscience.
“Lotus Neuro exists because science is not the problem, delivery is,” said Arjun “JJ” Desai, M.D., Founder and Chief Executive Officer of Lotus Neuro. He emphasized that brain diseases are complex and variable and require approaches capable of delivering treatments with a high degree of precision.
According to Desai, preclinical and clinical research conducted at leading neuroscience centers has demonstrated the potential for focused ultrasound to be combined with therapeutics and used to reach targeted areas throughout the brain.
Growing Clinical Evidence Base
Lotus Neuro is launching with an existing body of clinical and translational evidence supporting focused ultrasound-mediated BBB modulation. The platform has been used in approximately 600 treatment sessions involving conditions including brain tumors, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
The technology has also been evaluated with multiple therapeutic classes, providing evidence that focused ultrasound-mediated BBB modulation may have applications beyond a single disease or type of medicine.
In glioblastoma, a multicenter Phase 1/2 study published in The Lancet Oncology in 2025 reported a median overall survival of 31.3 months among patients who received standard chemotherapy with BBB opening, compared with 19.3 months in a matched control cohort. The study reported no treatment-related deaths.
While these findings require further validation in appropriately controlled clinical studies, Lotus Neuro views the results as evidence supporting continued investigation of focused ultrasound-assisted therapeutic delivery in aggressive brain cancers.
The technology has also been evaluated in Alzheimer’s disease. A study published in The New England Journal of Medicine in 2024 found greater amyloid plaque reduction in brain regions where the BBB was opened alongside aducanumab compared with corresponding untreated regions. The findings provided evidence that focused ultrasound-mediated BBB modulation could influence the distribution or effectiveness of an administered therapeutic in targeted areas.
In Parkinson’s disease, a Phase 1 study investigated repeated delivery of an enzyme replacement therapy to the putamen using focused ultrasound. The research demonstrated the feasibility of using the technology to support repeated therapeutic administration to a specific brain structure.
Additional evidence has emerged in patients with HER2-positive brain metastases. In research published in Science Translational Medicine in 2021, a radiolabeled antibody showed approximately twofold greater uptake in lesions treated with focused ultrasound compared with non-sonicated lesions.
The platform has also supported preclinical delivery studies involving gene therapy vectors and oligonucleotides in non-human primates. Separately, research in ALS demonstrated that the BBB could be opened safely over the motor cortex, adding to the evidence that focused ultrasound can be applied to anatomically defined regions relevant to neurological disease.
Addressing a Critical Challenge in CNS Drug Development
Lotus Neuro’s strategy is based on the idea that drug delivery and biological efficacy need to be evaluated separately. A therapeutic may fail to demonstrate clinical benefit because it does not adequately reach its intended target, even if the underlying biological mechanism is valid.
Ajay Verma, M.D., Ph.D., Founding Scientist of Lotus Neuro, said that many central nervous system drug trials have proceeded without first establishing whether the investigational therapy reached its intended brain target at a meaningful concentration.
Without such information, he explained, it can be difficult to determine whether an unsuccessful clinical outcome reflects an ineffective biological target or insufficient drug delivery.
Focused ultrasound could potentially help address this issue by enabling investigators to control where the BBB is modulated. This could provide an opportunity to evaluate target engagement and pharmacological effects more directly in patients.
The company is therefore positioning its technology not simply as a drug-delivery mechanism but also as a potential tool for improving the design and interpretation of neuroscience clinical trials.
Partnership-First Development Strategy
Lotus Neuro is launching with a partnership-focused business model. Rather than developing an extensive proprietary drug pipeline, the company intends to collaborate with pharmaceutical and biotechnology companies as well as academic research centers.
Through these collaborations, Lotus Neuro aims to combine its focused ultrasound platform with promising investigational medicines and determine whether targeted delivery can improve exposure and biological activity within the brain.
The company plans to use advances in blood, tissue and imaging analysis to characterize drug delivery and target engagement. Such measurements could help researchers determine whether a therapeutic reaches its intended site of action and whether it produces the expected biological response.
The company’s Proof of Pharmacology (POP) Challenge, launched in June 2026, is one component of this strategy. Through the initiative, Lotus Neuro is funding investigators at leading neuroscience institutions to incorporate focused ultrasound study arms into existing investigational drug programs.
The goal is to generate clinical evidence showing whether focused ultrasound can increase drug delivery and demonstrate target engagement in specific areas of the brain.
This approach could be particularly valuable for programs involving large molecules and advanced therapeutic modalities that have historically faced significant challenges crossing the BBB.
Modality-Agnostic Platform
Junghae Suh, Ph.D., Chief Technology Officer of Lotus Neuro, highlighted the flexibility created by the company’s decision not to modify the therapeutic itself.
Because the underlying drug can remain unchanged, Lotus Neuro believes its platform can advance alongside its partners’ existing development programs. This could allow the technology to be evaluated with different therapeutic approaches without requiring developers to redesign the medicine specifically for brain penetration.
The potential application across small molecules, antibodies, enzymes, gene therapies, oligonucleotides and cell therapies provides the company with a broad opportunity to explore combinations across neurological disorders.
However, the effectiveness of focused ultrasound-mediated delivery is expected to vary depending on the therapeutic modality, target tissue, disease biology and treatment objective. Continued clinical studies will therefore be important for determining where the approach provides the greatest therapeutic advantage.
From Medical Device to Therapeutic Delivery
Lotus Neuro’s formation creates a distinct focus within the broader Insightec ecosystem. Insightec will continue advancing and commercializing its core focused ultrasound platform, while Lotus Neuro will apply the technology to therapeutic drug delivery and neurological disease.
Maurice R. Ferré, M.D., Chairman and CEO of Insightec and a member of the Lotus Neuro Board of Directors, described the company’s creation as a continuation of focused ultrasound’s development from a technology used to affect brain tissue to a platform capable of supporting therapeutic delivery.
The companies will maintain scientific collaboration and share translational data while pursuing their respective areas of focus.
Scott Rakestraw, Ph.D., an independent director of Lotus Neuro, said the company combines a validated technology, a significant unmet medical need and an experienced team. He highlighted the potential of the platform across both brain cancer and neurodegenerative diseases.
Building a New Approach to Brain Therapeutics
With its public launch, Lotus Neuro is positioning focused ultrasound-assisted BBB modulation as a potential enabling technology for the next generation of neurological therapies.
The company’s strategy addresses a fundamental bottleneck in neuroscience: getting promising medicines to the right location in the brain at therapeutically meaningful concentrations. By combining precise ultrasound-based BBB modulation with existing therapeutic candidates, Lotus Neuro hopes to provide drug developers with another way to evaluate and potentially improve treatment delivery.
The company’s approximately 600 treatment sessions and clinical experience across brain tumors, Alzheimer’s disease, Parkinson’s disease and ALS provide a foundation for further development. At the same time, the company will need to generate additional clinical evidence to establish the safety, reproducibility and therapeutic value of combining focused ultrasound with specific medicines.
As Lotus Neuro moves forward with pharmaceutical partnerships, academic collaborations and its Proof of Pharmacology Challenge, its focus will remain on demonstrating whether precise delivery can translate into measurable pharmacological effects and improved outcomes for patients with focal neurologic diseases.
Alongside its corporate launch, Lotus Neuro has introduced its new brand identity and website, including The Lotus Neuro Story, featuring the company’s founders, scientific leadership and advisors. The launch marks the company’s next stage as it seeks to transform focused ultrasound from a clinically validated brain technology into a platform for delivering medicines to precisely targeted regions of the brain.
About Lotus Neuro
Lotus Neuro is a clinical-stage biotechnology company advancing brain-targeted therapeutics through precision, low-frequency focused ultrasound. Spun out of Insightec in December 2025, the company pairs a clinically validated platform for opening the blood-brain barrier with medicines of any modality, opening the barrier only where the disease is and letting it close again. Its initial clinical focus is neuro-oncology, with programs and partnerships in neurodegeneration and other focal neurologic disease. Lotus Neuro is headquartered in Miami.